<DOC>
	<DOCNO>NCT00768755</DOCNO>
	<brief_summary>AG-013736 ( axitinib ) combination cisplatin pemetrexed evaluate first-line treatment patient locally advance , recurrent , metastatic non-squamous , non small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis adeno , large cell bronchioalveolar nonsmall cell lung cancer Cytologic specimens diagnosis cell type classification must obtain bronchial brushing washing needle aspiration define lesion . Sputum cytology alone acceptable diagnosis cell type classification . Patients mixed NSCLC predominantly squamous cell carcinoma classify squamous thus qualify study . Stage IIIB malignant effusion ( cytologic confirmation malignant pleural pericardial effusion ) , Stage IV , recurrent disease definitive locoregional therapy . Candidate primary treatment cisplatin pemetrexed Any histological/cytological evidence predominantly squamous NSCLC . Small cell carcinoid lung cancer patient also ineligible . NSCLC classify one eligible histology ( adenocarcinoma , large cell bronchioalveolar ) . Prior systemic therapy Stage IIIB ( malignant effusion ) , Stage IV , recurrent NSCLC . ( Prior treatment systemic therapy adjuvant chemotherapy conjunction radiotherapy Stage II III NSCLC permit last dose chemotherapy complete 12 month prior randomization ) . Prior treatment VEGF VEGFR inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>non-squamous NSCLC</keyword>
	<keyword>axitinib</keyword>
	<keyword>pemetrexed/cisplatin</keyword>
</DOC>